Researchers flag metabolic cancer therapy

Science on June 2 amplified a cancer-metabolism study that points to a new way of slowing tumor growth: changing how bile acids are made in and around liver tumors. The paper, published in Science, examined hepatocellular carcinoma and experimental liver cancer models and found that altering conjugated bile acid synthesis changed the tumor microenvironment and improved antitumor immune activity. The study was circulated on X by ScienceMagazine in a post linking directly to the journal item. The paper does not present the work as a late-stage clinical result. Instead, the findings are described in human hepatocellular carcinoma samples and experimental model systems, with the mechanism centered on metabolism and tumor-specific T cell responses rather than a reported trial phase or headline efficacy figure. ### Which metabolic pathway did the researchers target? The study focused on bile acids, which are metabolites made in the liver and known mainly for helping digest fats. (science.org) The authors wrote that primary conjugated and secondary bile acids accumulated in human hepatocellular carcinoma and in experimental liver cancer models, making bile acid metabolism a central pathway in the work. The researchers said hepatocytes were the intervention point. (science.org) In the paper, they reported that inhibiting conjugated bile acid synthesis through deletion of the bile acid-conjugating enzyme bile acid–CoA:amino acid N-acyltransferase, or BAAT, changed immune activity in the tumor setting. ### How did the study say tumor growth was limited? The Science paper said BAAT inhibition “enhanced tumor-specific T cell responses, reduced tumor growth, and sensitized tumors to anti programmed cell death protein 1 (anti PD-1) immunotherapy.” That makes the reported antitumor effect less about directly poisoning cancer cells and more about reshaping the metabolic conditions around them. (science.org) The authors also described distinct effects from different bile acids. Primary bile acids induced oxidative stress in CD8-positive T cells, while the secondary bile acid lithocholic acid suppressed T cell function through endoplasmic reticulum stress, according to the paper. ### Why does this count as a metabolic cancer therapy story? Cancer metabolism research looks at how tumors use nutrients and metabolites to keep growing and to blunt immune attack. (science.org) Science’s paper fits that framework because it links a specific metabolic product — bile acids — to immune suppression in liver cancer and then tests whether changing that pathway can improve tumor control. A broader Science review on cancer metabolism has described metabolic activities such as glycolysis, glutamine use and redox control as core supports for tumor growth and proliferation. (science.org) The new liver-cancer study extends that logic to organ-specific metabolites in the tumor microenvironment, particularly bile acids. ### Was this shown in patients? The paper says bile acid accumulation was observed in human hepatocellular carcinoma, but the intervention results were reported in experimental liver cancer models. (science.org) The study text available through Science does not identify a clinical trial phase, patient enrollment, or a numerical response rate. That distinction matters because the work is best read as mechanistic and preclinical-to-translational research. (science.org) The authors said the findings show that modifying bile acid synthesis or dietary intake of ursodeoxycholic acid could improve tumor immunotherapy in liver cancer model systems. ### Who did the work, and what comes next? The author list on the Science paper includes researchers from the Salk Institute for Biological Studies, the University of California San Diego and Columbia University Irving Medical Center, among other institutions. (science.org) Susan M. Kaech, Gerald S. Shadel and Gen-Sheng Feng are among the senior authors listed on the paper. The next concrete step is in the paper itself: the authors point to modifying bile acid synthesis and testing dietary ursodeoxycholic acid as routes to improve immunotherapy in liver cancer model systems. (science.org) Any move into formal human testing would require later trial disclosures beyond the Science report now circulating.